BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26847174)

  • 1. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity.
    Larsen CP; Cossey LN; Beck LH
    Mod Pathol; 2016 Apr; 29(4):421-6. PubMed ID: 26847174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.
    Wang J; Cui Z; Lu J; Probst C; Zhang YM; Wang X; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Debiec H; Ronco P; Zhao MH
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1642-1651. PubMed ID: 28801527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.
    Tian C; Li L; Liu T; Qu X; Qiu Y
    Int Urol Nephrol; 2019 Aug; 51(8):1371-1377. PubMed ID: 31227982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Histological Features of Phospholipase A2 Receptor-Associated and Thrombospondin Type-I Domain-containing 7A-Associated Idiopathic Membranous Nephropathy: A Single Center Retrospective Study from China.
    Zhang D; Zou J; Zhang C; Zhang W; Lin F; Jiang G
    Med Sci Monit; 2018 Jul; 24():5076-5083. PubMed ID: 30032157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain.
    Fresquet M; Rhoden SJ; Jowitt TA; McKenzie EA; Roberts I; Lennon R; Brenchley PE
    J Autoimmun; 2020 Jan; 106():102308. PubMed ID: 31395435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans.
    Lwezaula BF; Ameh OI; Ekrikpo UE; Botha FC; Okpechi-Samuel US; Wearne N; Ronco P; Bello AK; Okpechi IG
    BMC Nephrol; 2021 Jan; 22(1):15. PubMed ID: 33413188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of M
    Gong Z; Yuan S; Zhu X; Wang Y; Yu F; Yang D; Xu X; Liu H; Li J; Sun L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jun; 45(6):693-700. PubMed ID: 32879127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers to detect membranous nephropathy in Chinese patients.
    Lin L; Wang WM; Pan XX; Xu J; Gao CN; Zhang W; Ren H; Xie JY; Shen PY; Xu YW; Ni LY; Chen N
    Oncotarget; 2016 Oct; 7(42):67868-67879. PubMed ID: 27634909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.
    L'Imperio V; Pieruzzi F; Sinico RA; Nebuloni M; Granata A; Smith A; Radice A; Pagni F
    J Nephrol; 2018 Aug; 31(4):543-550. PubMed ID: 29626294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings.
    Kaya B; Paydas S; Balal M; Eren Erdogan K; Gonlusen G
    Int J Clin Pract; 2021 Apr; 75(4):e13855. PubMed ID: 33249733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.
    Sethi S; Debiec H; Madden B; Charlesworth MC; Morelle J; Gross L; Ravindran A; Buob D; Jadoul M; Fervenza FC; Ronco P
    Kidney Int; 2020 Jan; 97(1):163-174. PubMed ID: 31901340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PLA2R and anti-THSD7A as Diagnostic Serological Markers of Idiopathic Membranous Nephropathy: A Single Centre Study.
    Fouad MA; Mahedy AW; Mansour AE; Fouad NA
    Egypt J Immunol; 2020 Jun; 27(2):1-9. PubMed ID: 33548972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of membranous nephropathy.
    Pozdzik A; Touzani F; Brochériou I; Corazza F
    Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):336-344. PubMed ID: 31045661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
    Zaghrini C; Seitz-Polski B; Justino J; Dolla G; Payré C; Jourde-Chiche N; Van de Logt AE; Booth C; Rigby E; Lonnbro-Widgren J; Nystrom J; Mariat C; Cui Z; Wetzels JFM; Ghiggeri G; Beck LH; Ronco P; Debiec H; Lambeau G
    Kidney Int; 2019 Mar; 95(3):666-679. PubMed ID: 30784662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLA2R and THSD7A: Disparate Paths to the Same Disease?
    Beck LH
    J Am Soc Nephrol; 2017 Sep; 28(9):2579-2589. PubMed ID: 28674044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare case of PLA2R- and THSD7A-positive idiopathic membranous nephropathy.
    Wanderley DC; Jones BD; Barbosa FAM; Araujo SA
    J Bras Nefrol; 2019 Oct; 42(2):254-258. PubMed ID: 31663595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN.
    Ren S; Wu C; Zhang Y; Wang AY; Li G; Wang L; Hong D
    Ren Fail; 2018 Nov; 40(1):306-313. PubMed ID: 29623759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.
    Zhang P; Huang W; Zheng Q; Tang J; Dong Z; Jiang Y; Liu Y; Liu W
    J Immunol Res; 2021; 2021():8163298. PubMed ID: 34337081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy.
    Zhang C; Zhang M; Chen D; Ren Q; Xu W; Zeng C; Qin W; Liu Z
    J Clin Pathol; 2019 Oct; 72(10):705-711. PubMed ID: 31243053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Membranous Nephropathy.
    Couser WG
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):983-997. PubMed ID: 28550082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.